指南与共识冠心病血脂与心血管预防

美国新胆固醇管理指南风险分层与急性冠脉综合征后阿利西尤单抗治疗的关系

Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes.
指南 / 共识 · Circulation · 2019-09-02

本研究基于ODYSSEY OUTCOMES试验,按2018年美国胆固醇管理指南对近期急性冠脉综合征且优化他汀治疗后仍存在血脂异常的患者进行风险分层。结果显示,指南定义的极高危患者缺血事件风险更高,阿利西尤单抗在各风险类别中相对风险降低一致,极高危患者绝对风险降低数值更大。

要点

  • 美国指南极高危标准可识别急性冠脉综合征后高复发缺血风险患者。
  • 阿利西尤单抗在极高危与非极高危患者中相对风险降低一致。
  • 极高危患者绝对风险降低数值更大,但未达统计学差异。

核心结论

  • 美国指南标准可识别近期急性冠脉综合征伴血脂异常且极高危的复发缺血事件患者,这些患者可能从阿利西尤单抗治疗中获得更大的绝对获益。

研究设计与样本

  • ODYSSEY OUTCOMES试验事后分析,纳入18 924例近期急性冠脉综合征且优化他汀治疗后仍存在血脂异常的患者,随机分配至阿利西尤单抗或安慰剂,中位随访2.8年。

主要发现

  • 11 935例(63.1%)被分类为极高危,其中4450例(37.3%)有多个既往动脉粥样硬化性心血管疾病事件,7485例(62.7%)有1个主要事件和多个高风险条件。
  • 安慰剂组中,极高危患者主要不良心血管事件发生率为14.4%,非极高危患者为5.6%。
  • 极高危组中,多个既往事件患者主要不良心血管事件发生率为20.4%,1个事件伴多个高风险条件患者为10.7%。
  • 阿利西尤单抗在极高危和非极高危组中相对风险降低一致(风险比=0.84 vs 0.86;交互作用P=0.820),极高危组内分层亦一致(风险比=0.86 vs 0.82;交互作用P=0.672)。
  • 阿利西尤单抗的主要不良心血管事件绝对风险降低在极高危组数值上大于非极高危组(2.1% vs 0.8%;交互作用P=0.095),极高危组内多个既往事件 vs 单个事件为2.4% vs 1.8%(交互作用P=0.661)。

关键数值与推荐

  • 2018年美国胆固醇管理指南推荐:对于二级预防患者,若最大耐受他汀治疗后低密度脂蛋白胆固醇≥70 mg/dL或非高密度脂蛋白胆固醇≥100 mg/dL,应考虑额外降脂治疗。
  • 极高危定义基于:>1个主要动脉粥样硬化性心血管疾病事件,或1个主要事件伴多个高风险条件。

临床怎么用

  • 对近期急性冠脉综合征且优化他汀治疗后仍存在血脂异常的患者,可按美国指南标准评估极高危状态。
  • 极高危患者可能从阿利西尤单抗治疗中获得更大的绝对风险降低,但需结合个体情况决策。

局限性

  • 绝对风险降低的组间差异未达统计学显著性(交互作用P=0.095和P=0.661)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The 2018 US cholesterol management guidelines recommend additional lipid-lowering therapies for secondary prevention in patients with low-density lipoprotein cholesterol ≥70 mg/dL or non-high-density lipoprotein cholesterol ≥100 mg/dL despite maximum tolerated statin therapy. Such patients are considered at very high risk (VHR) based on a history of >1 major atherosclerotic cardiovascular disease (ASCVD) event or a single ASCVD event and multiple high-risk conditions. We investigated the association of US guideline-defined risk categories with the occurrence of ischemic events after acute coronary syndrome and reduction of those events by alirocumab, a PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor. METHODS: In the ODYSSEY OUTCOMES trial (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab), patients with recent acute coronary syndrome and residual dyslipidemia despite optimal statin therapy were randomly assigned to alirocumab or placebo. The primary trial outcome (major adverse cardiovascular events, ie, coronary heart disease death, nonfatal myocardial infarction, ischemic stroke, or hospitalization for unstable angina) was examined according to American College of Cardiology/American Heart Association risk category. RESULTS: Of 18 924 participants followed for a median of 2.8 years, 11 935 (63.1%) were classified as VHR: 4450 (37.3%) had multiple prior ASCVD events and 7485 (62.7%) had 1 major ASCVD event and multiple high-risk conditions. Major adverse cardiovascular events occurred in 14.4% of placebo-treated patients at VHR versus 5.6% of those not at VHR. In the VHR category, major adverse cardiovascular events occurred in 20.4% with multiple prior ASCVD events versus 10.7% with 1 ASCVD event and multiple high-risk conditions. Alirocumab was associated with consistent relative risk reductions in both risk categories (hazard ratio=0.84 for VHR; hazard ratio=0.86 for not VHR; Pinteraction=0.820) and by stratification within the VHR group (hazard ratio=0.86 for multiple prior ASCVD events; hazard ratio=0.82 for 1 major ASCVD event and multiple high-risk conditions; Pinteraction=0.672). The absolute risk reduction for major adverse cardiovascular events with alirocumab was numerically greater (but not statistically different) in the VHR group versus those not at VHR (2.1% versus 0.8%; Pinteraction=0.095) and among patients at VHR with multiple prior ASCVD events versus a single prior ASCVD event (2.4% versus 1.8%; Pinteraction=0.661). CONCLUSIONS: The US guideline criteria identify patients with recent acute coronary syndrome and dyslipidemia who are at VHR for recurrent ischemic events and who may derive a larger absolute benefit from treatment with alirocumab. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov. Unique identifier: NCT01663402.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Roe MT, Li QH, Bhatt DL, et al. Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes. Circulation. 2019. PMID: 31475572. doi:10.1161/CIRCULATIONAHA.119.042551

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。